Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LVLAVA Therapeutics N.V. logo

LAVA Therapeutics N.V. (LVTX)

NASDAQ Global Select · Currency in USD
$1.74 ▼ -0.07 (-3.87%)
At close: Nov 28, 4:00 PM ET. Market closed.

Summary

Previous Close
$1.74
Open
$1.74
Day's Range
$1.74 – $1.74
52 Week Range
$0.85 – $2.00
Volume
285,521
Avg. Volume
346,585
Market Cap
$45.77M
Beta (5Y Monthly)
0.50
PE Ratio (TTM)
--
EPS (TTM)
-$0.59
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.75

Profile: LAVA Therapeutics N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
34
CEO
Stephen Allen Hurly

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer.

Earnings

DateEst.Actual
Nov 6, 2025-$0.23-$0.27Miss
Aug 13, 2025-$0.28-$0.32Miss
May 14, 2025-$0.37-$0.13Beat
Mar 28, 2025-$0.32-$0.14Beat
Dec 10, 2024-$0.33-$0.46Miss
Aug 20, 2024-$0.33-$0.31Beat

Analyst view

Consensus price target
$3.75 ▲ +115.5%
Range $1.50 – $6.00
Rating: Hold
Buy 33% · Hold 67% · Sell 0%

Get free alerts on LVTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.